Innate Pharma (IPHA) Return on Sales (2019 - 2025)

Innate Pharma (IPHA) has reported Return on Sales for 7 consecutive years, with 0.01% the latest figure, recorded in Q4 2025.

• Quarterly Return on Sales rose 3.0% year-over-year to 0.01% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.01% (changed 0.0% YoY) and the FY2022 annual result came in at 0.0%, changed 0.0% from the prior year.
• Return on Sales rose to 0.01% in Q4 2025 per IPHA's latest filing, from 0.04% in the prior quarter.
• Over the last five years, Return on Sales for IPHA reached as high as 0.0% in Q4 2022 and fell as low as 0.04% in Q4 2024.
• A 5-year average of 0.01% and a median of 0.0% in 2023 frame the typical range for Return on Sales.
• Annual changes were most pronounced in 2024 — Return on Sales dropped 4 bps — and 2025, when it rose 3 bps.
• Year by year, Return on Sales stood at 0.01% in 2021, then soared by 100 bps to 0.0% in 2022, then tumbled by 5520107 bps to 0.0% in 2023, then slumped by 2587 bps to 0.04% in 2024, then surged by 68 bps to 0.01% in 2025.
• According to Business Quant data, Return on Sales over the past three periods registered 0.01%, 0.04%, and 0.03% for Q4 2025, Q4 2024, and Q2 2024 respectively.